 |
 Video: What is a Stock Split?
|
|
|
| Decibel Therapeutics is a clinical-stage biotechnology company focused on discovering and developing transformative treatments for hearing and balance disorders. Co. is developing its primary gene therapy product candidate, DB-OTO, to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. In addition, Co. is advancing AAV.103 to restore hearing in individuals with mutations in the gap junction beta-2 gene and AAV.104 to restore hearing in individuals with mutations in the stereocilin gene. Co. is also developing DB-020 for the prevention of cisplatin-induced hearing loss, which it is evaluating in patients in a clinical trial. According to our Decibel Therapeutics stock split history records, Decibel Therapeutics has had 0 splits. | |
|
Decibel Therapeutics (DBTX) has 0 splits in our Decibel Therapeutics stock split history database.
Looking at the Decibel Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Decibel Therapeutics shares, starting with a $10,000 purchase of DBTX, presented on a split-history-adjusted basis factoring in the complete Decibel Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/16/2021 |
|
| End date: |
09/22/2023 |
|
| Start price/share: |
$18.10 |
|
| End price/share: |
$4.91 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-72.87% |
|
| Average Annual Total Return: |
-39.52% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$2,712.61 |
|
| Years: |
2.59 |
|
|
|
|
|
